Whereas government agencies in Canada, Australia European countries set limits on the cost of prescription drugs, in the United States, thanks to a laissez faire government pass, pharmaceutical companies are encouraged to set prescription drug prices however high they wish without any . . . Continue reading →
1967-1968: Grünenthal executives were put on trial in Aachen, Germany The indictment charged the company with intent to commit bodily harm and involuntary manslaughter. The central defendant was Dr. Heinrich Mückter, an indicted Nazi war criminal, who was the company’s chief scientist . . . Continue reading →
“How Men Who Blighted Lives of thousands Evaded Justice.” The post-WWII horror story of thalidomide begins in the picture-book town of Stolberg, near Aachen, in western Germany, with the establishment of Chemie Grünenthal, a Wirtz family-owned pharmaceutical company. After WWII, Nazi scientists stared . . . Continue reading →
The following announcement was posted on TeenScreen’s website (November 15, 2012): "Important Announcement for Schools & Communities: We are sorry to inform you that the TeenScreen National Center will be winding down its program at the end of this year. Accordingly, . . . Continue reading →
Part III. The Untouchable Third Rail in Healthcare—The Vaccine Controversy: Core Issues Continue reading →
Part II. What Do We Get for All That Money? A preventable epidemic of injury and death from prescription drugs; FDA’s contribution to the epidemic; Big Pharma’s business model: manufactured myths, propaganda and a hidden agenda;
Autism: Vaccine Injury Compensation Program (VICP) data. Continue reading →
The decision to suspend the trial is viewed as highly questionable, raising disturbing questions about the role that marketing played–especially in light of the fact that Zytiga’s patent is due to expire in 2017.
Johnson & Johnson officilas made a business decision to decieve doctors by lying about the diabetes risk: “how much commercial liability would we incur if we sent a similar letter about Risperdal”? Continue reading →
The FDA granted market exclusivity to KV for an old drug that had been available from special pharmacies that custom-compound treatments not approved by the FDA, for $20 a shot. By granting KV market exclusivity, women could no longer obtain the drug, Makena, at a reasonable price– KV set the price at $1,500 a shot. Continue reading →
The Coalition Against Bayer pharmaceuticals (CBG) announces that Bayer and Baxter settled a mulit-million dollar compensation suit with hemophiliacs in 22 countries who were victims, infected with HIV or hepatitis C having been infused with tainted blood plasma products in the 1980s. . . . Continue reading →
From 1991-2000 qui tam law suits accounted for only 9% of settlements with the government. But from 2001-2010, qui tam settlements comprised 67% of the billions in payouts Continue reading →
